Gilead's Sovaldi Wins Backing of UK Health-Cost Regulator - Businessweek

[INCIID News Feed]

Gilead's Sovaldi Wins Backing of UK Health-Cost Regulator Businessweek Gilead Sciences Inc. (GILD:US)'s hepatitis C drug Sovaldi won the backing of the U.K.'s health-cost regulator, paving the way for the treatment to be reimbursed by British taxpayers at a price of almost $700 a pill. A standard 12-week course of Sovaldi will cost ... UK Recommends Covering Sovaldi Hepatitis PillWall Street Journal (blog) Financial Times UK cost body backs pricey Gilead hepatitis pill for some patientsReuters India all 17 news articles »

More...